|
|
www.icpermed.eu
| twitter.com/icpermed |
|
|
Disclaimer for COVID-19 |
Due to the COVID-19 situation, ICPerMed and the
European Commission have been continuously in contact
since the emergency started. Please be informed that the
information in this newsletter is susceptible for
variation in the next months; all updates will be
provided in the news section on the ICPerMed website.
|
back to top
| | |
ICPerMed conference ‘Personalised
Medicine – From Vision to Practice” in Paris – programme
released |
We are pleased to announce that the
preliminary programme for the ICPerMed conference
‘Personlised Medicine – From Vision to Practice’ is now
available.
Due to the COVID-19 pandemic, the second ICPerMed
Conference, initially scheduled for October 15-16, 2020,
will now take place in February 25-26, 2021 in
Paris at La Maison de la Chimie.
The conference will gather renowned experts in the
field of personalised medicine from all across the world
and will feature five distinct sessions closely related
to the ICPerMed
Vision Paper:
- Session 1: Informed and engaged citizens -
personalised medicine for the individual and society.
- Session 2: Enhancing life science - and
health-related data through biomedical research, data
harmonisation and regulatory frameworks.
- Session 3: Enabling healthcare systems to
implement the next generation of medicine: a crucial
shift.
- Session 4: Building an efficient
entrepreneurial ecosystem supporting health
innovation.
- Session 5: Personalised medicine, an
opportunity to redefine value in healthcare by
incorporating patient preference and socio-economics
aspects.
A sixth session on “The challenges to a
Personalised Medicine Approach for infectious diseases –
Lessons learned from the COVID-19 pandemic (Working
title)” will be dedicated to the COVID-19 pandemic and
how personalised medicine approaches could be part of
the solutions.
Furthermore, ICPerMed will feature and honour during
the event best practices in personalised medicine
research through the ICPerMed Recognition 2020,
aiming to recognise, encourage, promote and disseminate
outstanding examples.
Given the COVID-19 pandemic and global restrictions,
ICPerMed understands that there are still some
uncertainties around events and international travel.
Therefore, ICPerMed is, besides the on-site format, also
preparing a virtual format assuring that all
participants will be able to attend the conference. We
will keep you informed via the ICPerMed website and
Twitter.
Further information on the programme
and the speakers
is available on the ICPerMed website. If you are
interested in participating, please register here.
|
back to top
| | |
New ICPerMed chair and vice chair
elected |
ICPerMed is glad to announce that Ejner Moltzen from
Innovation Fund Denmark has been elected new chair of
the ICPerMed Executive Committee and Hemma Bauer from
the Federal Ministry of Science, Research and Economy in
Austria has been elected new vice chair of the ICPerMed
Executive Committee |
Ejner Moltzen, ICPerMed chair |
Hemma Bauer, ICPerMed vice
chair |
They will succeed Jan-Ingvar Jönsson as chair and
Wolfgang Ballensiefen as vice chair, whom ICPerMed
thanks her for their valuable and enthusiastic
support! |
back to top
| | |
COVID-19 and Personalised Medicine
|
Professor Yazdan Yazdanpanah and his colleague Dr
Olivier Robineau share with ICPerMed their first lessons
learned on the health crisis and the contribution of
personalised medicine approaches to fight infectious
diseases through the light of the COVID-19 pandemic:
“The SARS-COV-2 epidemic has and will continue to
affect millions of people. In the context of a rapidly
spreading new virus, it is urgent to take measures to
limit its spread and to develop therapeutic solutions
that can be used on a large scale. Thus, personalised
medicine (PM) could appear to be a secondary issue in
this world health emergency. However, the great
variability in the evolution of the epidemic and the
extremely polymorphic nature of patients' clinical
course confirm that there are no simple, universal
solutions to the pandemic in terms of both public health
and therapeutic management. More generally, the
management of epidemics and emerging viruses must be
able to rely on the tools and researchers involved in
personalised medicine.” (Excerpt from the
commentary available on the ICPerMed
website.)
Professor Yazdanpanah and Dr Robineau outline how
personalised medicine could contribute to handle the
COVID-19 crisis around six different challenges:
- Clinical forms, management and outcome: a great
heterogeneity
- Sequelae and long-term consequences
- Epidemiological surveillance and public health
measures
- Genetic and transcriptomic research
- Research on Meta-data and big data
- Therapeutic research: molecule repositioning and
translational research
They conclude that “(…) this epidemic offers the
opportunity to objectify how specific the encounter
between an infectious agent and a living being is, and
to seek how to go beyond the principles of infectious
disease management, a formalised management for a
disease, towards an individualised
management.”
The entire comment is available on the ICPerMed
website.
|
Professor Yazdan
Yazdanpanah is the Head of the Infectious
Disease Department at the Bichat Claude-Bernard
Hospital in Paris and is one of the 13 members of
the COVID-19 scientific council, responsible for
advising the government on the management of the
health crisis. In 2014, he was in charge of
coordinating the fight against epidemics within
the REACTing
consortium (REsearch and ACTion targeting
emerging infectious diseases). He supervised the
surveillance of the emergence of SARS epidemics in
2002-2003 and of the H1N1 influenza in 2009. On
January 24, 2020, he treated the first patients of
COVID-19 in France. |
|
Dr Olivier Robineau,
infectious diseases specialist and doctor
in the Academic/University Department of
Infectious Diseases and Travelers at Gustave Dron
in Tourcoing, has been appointed to coordinate a
large national study, Cocolate, within the
REACTing consortium. The study aims to analyse the
consequences/sequels in patients with severe or
mild form of COVID-19. |
|
back to top
| | |
Update on preparations of European
Partnership on Personalised Medicine (EP PerMed) under
Horizon Europe |
In preparation of the European Commission’s member
states consultation for the co-funded European
Partnership for Personalised Medicine, taking place most
probably at the end of 2020 or beginning of 2021,
ICPerMed together with ERA PerMed developed a supporting
document in form of a concept paper that was officially
passed on to the European Commission on October 13,
2020.
Already in December 2019, ICPerMed published together
with ERA PerMed a statement
concerning the new European
Partnerships to be developed within Horizon Europe,
the next EU research and innovation framework programme,
and in particular the potential European Partnership for
Personalised Medicine (see also ICPerMed special
newsletter from July 2020). Thereafter, ICPerMed and
ERA PerMed joined forces and formed together with
representatives of the European Commission a preparatory
group to develop the European
Partnership for
Personalised Medicine
– EP PerMed concept paper.
The concept paper outlines how the EP PerMed could be
a prime driver for developing and implementing
Personalised Medicine by establishing priorities for
research funding, aligning Personalised Medicine
strategies, developing educational and literacy
strategies, and supporting policy development.
ICPerMed and ERA PerMed discussed the concept paper
and needed steps towards the EP PerMed in a Joint
Sustainability Workshop on 10-11 September 2020.
Taking together ICPerMed and ERA PerMed, more than 54
funding organisations and ministries from 34 countries
(24 out of 27 EU member states, 6 associated countries
and 4 third countries) are supporting the European
Partnership for Personalised Medicine.
“The EP PerMed aims to foster advancements in
Personalised Medicine by joint research funding efforts,
creating a dialogue platform for all relevant
stakeholders and providing a forum for promoting novel
evidence to decision makers regarding current challenges
and possible solutions in the implementation of
Personalised Medicine. The EP PerMed will add value by
bridging the gap between Personalised Medicine research
and its implementation in healthcare systems, by
bringing together all the stakeholders involved in this
field in the partnership.” (EP PerMed concept paper)
|
back to top
| | |
ICPerMed Recognition 2020 – winners
chosen |
The winners of the ICPerMed “Best Practice in
Personalised Medicine” Recognition 2020 are:
- A pathology-supported genetic testing platform
for application of breast cancer pharmacogenetics at
the point of care (POC) using an integrated service
and research approach.
Maritha Kotze
(Department of Pathology, Stellenbosch University and
National Health Laboratory Service – NHLS - Tygerberg
Hospital - South Africa); Dr van der Merwe (Department
of Pathology, Stellenbosch University - South Africa);
Prof Rajiv Erasmus (Stellenbosch University - South
Africa); Dr Armand Peeters (Pathology Research
Facility (PRF) at Stellenbosch University's Faculty of
Medicine and Health Sciences-South Africa).
- The Personalised Medicine Coalition: Developing
Strategies for the Integration of Personalised
Medicine in Health Care Practice.
Daryl
Pritchard (Senior Vice President of Science Policy at
the Personalised Medicine Coalition, PMC, USA); PMC
representing a collaboration of more than 230
organisations
- A combined ANXA2-NDRG1-STAT1 gene signature
predicts response to chemoradiotherapy in cervical
cancer.
Daniela Gallo (Sacro Cuore Cattolica
University, Rome, Italy); M. Buttarelli; G. Babini; G.
Raspaglio; F. Filipetti; A. Battaglia; A. Ciucci; G.
Ferrandina; M. Petrillo; C. Marino; M. Mancuso; A.
Saran; M. E. Villani; A. Desiderio; C. D'Ambrosio; A.
Scaloni; G. Scambia
- International Tinnitus Research – Novel
approaches in Personalised Medicine
Research.
Winfried Schlee (University
Regensburg, Regensburg, Germany) and
colleagues
The selected authors will be invited to the ICPerMed
Conference ‘Personalised Medicine – From Vision to
Practice” on February 25-26, 2021 and will be given the
opportunity to present their results during a plenary
session to stakeholders interested in the area of
Personalised Medicine. In addition, the successful
candidates will receive a non-cash support for the
dissemination of their best practice examples by the
ICPerMed Secretariat in the value of 500 euros.
The five proposals in fourth position will be invited
to present a poster of their work during the ICPerMed
Conference 2021. These are:
- Connecting the Austrian PerMed Community: The
Austrian Platform for Personalized Medicine. Philipp
Hofer on behalf of the Board of the Austrian Platform
for Personalized Medicine
(Medical University
of Vienna, Austria)
- EURAT-Consortium
Eva Winkler
(University Heidelberg, Germany); Irina Idler
(University Heidelberg, Germany)
- Health outcomes, utility and costs of returning
incidental results from genomic sequencing in a
Canadian cancer population: protocol for a
mixed-methods randomized controlled trial.
Yvonne Bombard (Li Ka Shing Knowledge Institute of
St. Michael’s Hospital. Toronto, Canada); Jordan
Lerner-Ellis; Raymond Kim; Kevin Thorpe
- Cell “Mechanomics” - a novel approach for
cancer diagnosis and personalized therapy.
Ofra Benny (Hebrew University of Jerusalem,
Israel)
- Reproducibility of the Nanostring 22-gene
molecular subgroup assay for improved prognostic
prediction of medulloblastoma.
Leticia Ferro
Leal (Barretos Cancer Hospital, Brasil); Adriane Feijò
Evangelista; Flavia Escremim de Paula; Rui Manuel Reis
The ICPerMed Recognition was created on the basis of
the evident impact of sharing best practice examples on
PM and will continue in the next years as an opportunity
to disseminate best practice research example to the
scientific community and all actors interested in
Personalised Medicine research.
The ICPerMed Recognition 2021 call on ‘Implementation
of Personalised Medicine research’ is planned to be
launched in 2021. |
back to top
| | |
Virtual ICPerMed Executive Committee
Meeting on October 13-14, 2020 |
On October 13-14, 2020, the ICPerMed Executive
Committee met virtually to discuss and plan strategy and
future activities of the consortium as well as
associated adaptations to the ICPerMed governance
structure.
At the meeting, the Executive Committee discussed
future events of ICPerMed, such as the next ICPerMed
Conference (February 25-26, 2021) and an ICPerMed Family
Meeting to take place in autumn 2021.
It was further discussed how ICPerMed can support the
planned European Partnership on Personalised Medicine
(EP PerMed). This partnership is foreseen to be
implemented under Horizon Europe, the next EU research
and innovation framework programme. ICPerMed strongly
supports this new partnership and developed together
with ERA PerMed a concept paper as input and supporting
document for the Member States consultation organised by
the EC.
The meeting was complemented by several guest
speakers who gave very interesting talks:
- Anthony Humphreys (Head of Regulatory Science and
Innovation) and Ivana Silva (Healthcare Professionals
and Learned Societies, Public Engagement Department,
Stakeholders and Communication Division) from the
European Medicines Agency (EMA) presented EMA’s
Regulatory Science Strategy and possible interactions.
- Further, the coordinators of three new
ICPerMed-related Coordination and Support Actions
funded by the European Commission presented their very
intriguing projects:
- PERMIT (Personalised
Medicine Trials) was presented by Jacques Demotes,
Director General ECRIN, Paris, France - IC2PerMed
(Integrating China in the International Consortium for
Personalised Medicine) was presented by Chiara Cadeddu
(Università Cattolica del Sacro Cuore & Istituto
Superiore di Sanità, Rome, Italy) - Sino-EU PerMed
(Cooperation between China and Europe in Personalised
Medicine) was presented by Carolin Lange and Sabine
Puch from DLR Project Management Agency, Bonn,
Germany.
The next ICPerMed Executive Committee Meeting will
take place on February 23-24, 2021, back to back with
the ICPerMed Conference. |
back to top
| | |
Update on ERA PerMed |
Results of Joint Transnational Call
2020
The ERA PerMed Third Joint Transnational Call
(JTC2020) ‘Personalised Medicine- pre-/clinical
research, big data and ICT, implementation and user’s
perspective’ had the support of 31 funding organisations
from 23 countries.
The call received 188 eligible pre-proposals. After a
first evaluation, among them 52 consortia were invited
to submit a full-proposal. Finally, 18 research projects
are expected to be funded following the recommendation
of the Peer Review Panel and will receive a total
funding of approximately 23 million euros.
Joint Transnational Call 2021-
pre-announcement
ERA PerMed is fostering the implementation of the
ICPerMed Action Plan by funding transnational research
projects in the field of personalised medicine. As is
stated in the pre-announcement on the ERA PerMed
website, a fourth Joint Transnational Call (JTC2021) for
collaborative innovative research projects in
personalised medicine will be launched in December 2020,
with a submission deadline for pre-proposals in March
2021. It will be supported by 28 funding organisations
with an available budget of approximately 16 million
euros. The topic of the call will be ‘Multidisciplinary
research projects on personalised medicine - Development
of clinical support tools for personalised medicine
implementation’. The following countries are already
participating in the preparation of the call: Belgium,
Croatia, Denmark, Finland, France, Egypt, Estonia,
Germany, Hungary, Israel, Italy, Latvia, Luxembourg,
Norway, Panama, Poland, Romania, Spain, Sweden and,
Turkey; with the following five regions: Saxony
(Germany), Lombardy (Italy), Tuscany (Italy), Catalonia
(Spain) and Navarre (Spain); and one charity (AECC-FC).
The Joint Call Secretariat is hosted by the Italian
Ministry of Health (It-MoH) with the support of
Fondazione Regionale per la Ricerca Biomedica (FRRB).
Email address: healthresearch@sanita.it.
For further information about the JTC2021, please refer
to the ERA PerMed
website.
New ERA PerMed Twitter account:
Please follow us on @ERANET_PerMed!
|
back to top
| | |
News from the ICPerMed-related CSAs
|
EULAC PerMed: Upcoming events
New interesting events are coming in November within
the activities planned by EULAC PerMed for 2020: The 3rd
Summer School and the 2nd Technical Workshop, both on
Ethical, Legal and Social Aspects (ELSA) of Personalised
Medicine and in a virtual format due to the Covid-19
global pandemic.
With the invaluable support of an ELSA Task Force set
by seven international experts of recognized expertise
that have designed an attractive and complete programme,
a 2nd Technical Workshop on ELSA will take place on
November, 17 -18, 2020. The objective is to exchange
insights on key ethical, legal and social issues in
Personalised Medicine research and implementation in
Europe and in Latin America and the Caribbean, and to
identify recommendations for future bi-regional
collaborations in the field of Personalised Medicine.
To complete this fascinating topic, during three
days, November 24-26, 2020, the 3rd Summer School
entitled ‘Implementation Research in Personalised
Medicine: ELSA perspective’ will give the opportunity
for participants to learn about research on ethical,
legal and social aspects existing in Personalised
Medicine and the development of strategies for use of
available and new tools to address these aspects.
Finally, and within the cycle of webinars organized
by EULAC PerMed on ‘Lessons to learn on Covid-19 from
PM’, the next webinar will be on November 5, 2020, by
Dr. Marcus Lacerda, Brazilian MD and PhD, who will share
with attendees his current experience on Covid-19
More information on these upcoming events can be
found on the EULAC
PerMed website.
IC2PerMed: Report from Chinese
Congress 2020 ‘3rd International Computational Law
online forum’
Thanks to the invitation from Tsinghua University,
the project ‘Integrating China in the International
Consortium for Personalised Medicine - IC2PerMed’ had
the chance to attend the Chinese Congress 2020 ‘3rd
International Computational Law online forum –
Development of intelligent industry and reconstruction
of legal institution’, organised by the School of Law of
Tsinghua University and held virtually on September
19-20, 2020.
The key topics of the online forum have been:
- Federating health data to allow secure cross
border access
- Precision Medicine from the perspective of ethics
- Application and practice of information network
data in pharmaceutical policy research
- Clinical application of medical technology - the
management of negative list
- Regulations and laws that promote the practice of
precision medicine
- Enlightenment from comparison between the internet
medical policy in China and US.
IC2PerMed has been presented in this occasion during
a session named ‘Precision Medicine: Technological
Development & Ethical and Legal Responsible’.
SAPHIRe: News from Securing the
Adoption of Personalised Health in regions
Webinar: Exit strategies for COVID-19
lockdown, what role do regions play?
On June 16, 2020, SAPHIRe hosted an interactive
webinar to gain a regional perspective on COVID-19
lockdown measures as a result of the ongoing global
pandemic. Topics discussed included the impact of a
lockdown on healthcare systems; enabling digital
transformation within hospitals and data-driven
healthcare; ICT care services for seniors, and sports
and vitality in the post-COVID-19 era. All of the
presentations are available on our website.
Webinar: COVID-19 contact tracing -- the
usefulness of mobile apps
On October 9, 2020, SAPHIRe hosted a webinar to
examine the usefulness of mobile apps for contact
tracing in different European regions. Speakers from
Northern Ireland, the Republic of Ireland, Poland,
Flanders and Antwerp all discussed how their regions
approached the contract tracing issue using mobile
technology. The recorded webinar presentations are
available to watch here.
Webinar: Access to health data: the role of
regional actors, gatekeepers, providers and
individuals
On October 29, 2020, SAPHIRe hosted the webinar
‘Access to health data: the role of regional actors,
gatekeepers, providers and individuals’. The topics
discussed included health data from different
points-of-view, and regional actors such as research
institutions, hospitals, industry and individuals were
heard. More information on the webinar is available here.
|
back to top
| | |
Facts: |
- ICPerMed started in November 2016
- 47 funding organisations
- 29 countries
- 5 Challenge Groups: Citizens & Patients, Data &
ICT,Research Efforts, Market Access, Health Systems
- 5 Action Item Groups (AIG):
- AIG1 – Data and ICT – Enabling Technology
- AIG2 – Data and ICT – Improving Health Care
- AIG3 – Translational Research
- AIG4 – Health Economics, Regulation, Market Access
- AIG5 – People and Society
| |
| |